[Premature ejaculation].
With prevalence rates of 20%-25% premature ejaculation (PE) represents the most frequent sexual dysfunction in men. Whereas genetically determined changes in the serotonin receptor-/transporter mechanism seem to be responsible for lifelong PE, acquired PE is often associated with other conditioning diseases such as erectile dysfunction, prostatitis or thyroid dysfunctions. Typical features of PE are a short intravaginal ejaculatory latency time (IELT) <1-2 min, lack of control over ejaculation, personal distress and partner problems. Treatment of PE subdivides into sexual therapy as well as drug therapy. Among the medications considered for PE, oral therapy with selective serotonin re-uptake inhibitors (SSRI), Dapoxetine (the first officially approved medication for PE) and topical therapy with lidocaine/prilocaine-containing medications are given priority.
Porst
H
H
Porst20354@aol.com
D000779:Anesthetics, Local / Q000627:therapeutic use; D001596:Benzylamines / Q000627:therapeutic use*; D004542:Ejaculation / Q000187:drug effects*; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use*; D008297:Male; D008388:Marital Therapy; D009281:Naphthalenes / Q000627:therapeutic use*; D011318:Prilocaine / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000628:therapy*
D000779:Anesthetics, Local; D001596:Benzylamines; D008012:Lidocaine; D009281:Naphthalenes; D011318:Prilocaine; D017367:Selective Serotonin Reuptake Inhibitors; C080598:dapoxetine